Dempze Nancy E maintained its stake in Merck & Co. (NYSE:MRK) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,083 shares of the company’s stock at the end of the second quarter. Merck & Co. comprises about 1.2% of Dempze Nancy E’s investment portfolio, making the stock its 29th largest position. Dempze Nancy E’s holdings in Merck & Co. were worth $696,000 as of its most recent filing with the SEC.
A number of other large investors have also recently bought and sold shares of MRK. Carroll Financial Associates Inc. raised its stake in shares of Merck & Co. by 15.2% in the first quarter. Carroll Financial Associates Inc. now owns 14,228 shares of the company’s stock valued at $752,000 after buying an additional 1,880 shares during the last quarter. Tompkins Financial Corp increased its position in Merck & Co. by 4.8% in the first quarter. Tompkins Financial Corp now owns 44,472 shares of the company’s stock valued at $2,352,000 after buying an additional 2,020 shares during the period. UMB Bank N A MO increased its position in Merck & Co. by 0.3% in the first quarter. UMB Bank N A MO now owns 306,974 shares of the company’s stock valued at $16,242,000 after buying an additional 903 shares during the period. Cornerstone Investment Partners LLC increased its position in Merck & Co. by 3.8% in the first quarter. Cornerstone Investment Partners LLC now owns 17,071 shares of the company’s stock valued at $903,000 after buying an additional 622 shares during the period. Finally, OLD National Bancorp IN increased its position in Merck & Co. by 5.0% in the first quarter. OLD National Bancorp IN now owns 93,883 shares of the company’s stock valued at $4,967,000 after buying an additional 4,484 shares during the period. Hedge funds and other institutional investors own 72.93% of the company’s stock.
Shares of Merck & Co. (NYSE:MRK) traded up 0.18% during trading on Friday, hitting $62.77. 10,775,249 shares of the company traded hands. Merck & Co. has a 52 week low of $47.97 and a 52 week high of $64.00. The company has a market capitalization of $173.57 billion, a price-to-earnings ratio of 34.43 and a beta of 0.68. The company has a 50 day moving average price of $62.66 and a 200 day moving average price of $58.40.
Merck & Co. (NYSE:MRK) last released its quarterly earnings data on Friday, July 29th. The company reported $0.93 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.91 by $0.02. Merck & Co. had a net margin of 13.01% and a return on equity of 23.41%. The business earned $9.84 billion during the quarter, compared to analyst estimates of $9.79 billion. During the same quarter last year, the business earned $0.86 earnings per share. Merck & Co.’s quarterly revenue was up .6% compared to the same quarter last year. On average, analysts expect that Merck & Co. will post $3.75 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 7th. Shareholders of record on Thursday, September 15th were given a dividend of $0.46 per share. The ex-dividend date of this dividend was Tuesday, September 13th. This represents a $1.84 annualized dividend and a yield of 2.93%. Merck & Co.’s dividend payout ratio (DPR) is currently 101.10%.
Several research analysts recently commented on MRK shares. Barclays PLC raised their price objective on shares of Merck & Co. from $66.00 to $72.00 and gave the stock an “overweight” rating in a report on Friday, September 9th. Jefferies Group raised their price objective on shares of Merck & Co. from $53.00 to $57.00 and gave the stock a “hold” rating in a report on Monday, August 8th. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $74.00 price objective (up from $66.00) on shares of Merck & Co. in a report on Thursday, August 11th. Morgan Stanley set a $60.00 price objective on shares of Merck & Co. and gave the stock a “hold” rating in a report on Tuesday, September 13th. Finally, BMO Capital Markets raised shares of Merck & Co. from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $62.00 to $72.00 in a report on Friday, August 5th. One analyst has rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of €63.20 ($70.23).
In other news, Chairman Kenneth C. Frazier sold 392,000 shares of the firm’s stock in a transaction dated Friday, August 5th. The shares were sold at an average price of €61.81 ($68.68), for a total value of €24,229,520.00 ($26,921,688.89). Following the completion of the sale, the chairman now owns 760,877 shares in the company, valued at approximately €47,029,807.37 ($52,255,341.52). The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Weir Mirian M. Graddick sold 40,800 shares of the firm’s stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of €62.07 ($68.97), for a total transaction of €2,532,456.00 ($2,813,840.00). Following the completion of the sale, the insider now owns 128,973 shares of the company’s stock, valued at approximately €8,005,354.11 ($8,894,837.90). The disclosure for this sale can be found here. Company insiders own 0.05% of the company’s stock.
Merck & Co. Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.